Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
10.21
+0.14 (1.39%)
At close: Jul 25, 2025, 4:00 PM
10.18
-0.03 (-0.29%)
After-hours: Jul 25, 2025, 7:52 PM EDT
Organon & Co. Revenue
Organon & Co. had revenue of $1.51B in the quarter ending March 31, 2025, a decrease of -6.72%. This brings the company's revenue in the last twelve months to $6.29B, down -0.84% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.29B
Revenue Growth
-0.84%
P/S Ratio
0.42
Revenue / Employee
$629,400
Employees
10,000
Market Cap
2.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
OGN News
- 3 days ago - Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 - Business Wire
- 4 days ago - OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN - PRNewsWire
- 5 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - GlobeNewsWire
- 14 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - GlobeNewsWire
- 15 days ago - OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN) - GlobeNewsWire
- 18 days ago - Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Business Wire
- 22 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - PRNewsWire
- 23 days ago - Karolinska Development receives update from Organon concerning OG-6219 - GlobeNewsWire